Dopaminergic drugs in development for Parkinson's disease
Korczyn, A.D.
Advances in Neurology 91: 267-271
2003
ISSN/ISBN: 0091-3952 PMID: 12442685 Document Number: 565630
Document emailed within 1 workday
Related Documents
Prabhakar, S.; Syal, P.; Srivastava, T. 2000: P300 in newly diagnosed non-dementing Parkinson's disease: effect of dopaminergic drugs Neurology India 48(3): 239-242Johnston, T.H.; Brotchie, J.M. 2004: Drugs in development for Parkinson's disease Current Opinion in Investigational Drugs 5(7): 720-726
Johnston, T.H.; Brotchie, J.M. 2006: Drugs in development for Parkinson's disease: an update Current Opinion in Investigational Drugs 7(1): 25-32
Zabek, M.; Mazurowski, W.; Dymecki, J.; Stelmachów, J.; Gawur, B.; Trautsolt, W.; Zawada, E. 1992: Transplantation of fetal dopaminergic cells in Parkinson disease Neurologia i Neurochirurgia Polska Suppl 1: 13-19
Agnoli, A.; Stocchi, F.; Carta, A.; Antonini, A.; Bragoni, M.; Ruggieri, S.A. 1988: Continuous dopaminergic stimulation in the management of complicated Parkinson's disease Mount Sinai Journal of Medicine new York 55(1): 62-66
Duvoisin, R.C. 1989: New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation Neurology 39(11 Suppl 2: 4-6
Ishida, Y. 2005: Psychiatric symptoms of Parkinson's disease--an overview from the studies on dopaminergic nerves Seishin Shinkeigaku Zasshi 107(3): 290-293
1997: Therapy of Parkinson disease. Continuous physiologic dopaminergic stimulation with carbergoline Der Nervenarzt 68(3 Suppl Therapie D): 1-4
Clough, C.G.; Bergmann, K.J.; Yahr, M.D. 1984: Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration Advances in Neurology 40: 131-140
Hirsch, E.C. 2000: Nigrostriatal system plasticity in Parkinson's disease: effect of dopaminergic denervation and treatment Annals of Neurology 47(4 Suppl 1): S115
Bertrand, E.; Lechowicz, W.; Szpak, G.M.; Dymecki, J. 1997: Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease Neurologia i Neurochirurgia Polska 31(2): 295-302
Melamed, E.; Hefti, F.; Wurtman, R.J. 1982: Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model Israel Journal of Medical Sciences 18(1): 159-163
Pokhabov, D.V.; Rudnev, V.A.; Prokopenko, S.V. 2003: The experience of dopaminergic agent decreased dosage with rhythmic pace gait correction in Parkinson disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 103(8): 76-77
Zheng, L.; Wang, H.; Ba, Y.-Y.; Liu, H.-L.; Wang, M.; Guo, W.-W.; Wu, X.; Yang, H. 2014: Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease Zhongguo Zhong Yao Za Zhi 39(9): 1660-1665
Hasegawa, K. 2000: The new Parkinson's disease drugs Nihon Rinsho. Japanese Journal of Clinical Medicine 58(10): 2066-2071
Weiner, W.J.; Shulman, L.M.; Oertel, W.H. 1999: Do we need more drugs to treat Parkinson's disease? Advances in Neurology 80: 481-483
Meco, G.; Casacchia, M.; Lazzari, R.; Franzese, A.; Castellana, F.; Carta, A.; Iannuccelli, M.; Agnoli, A. 1984: Mental impairment in Parkinson's disease. the role of anticholinergic drugs Acta Psychiatrica Belgica 84(4): 325-335
Guillard, A. 1989: Development of Parkinson's disease La Revue du Praticien 39(8): 653-657
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Martínez-Suárez, M.M.; Blázquez-Menes, B. 2000: Estimation of the prevalence of Parkinson's disease in Asturia, Spain. a pharmacoepidemiological study of the consumption of antiparkinson drugs Revista de Neurologia 31(11): 1001-1006